John Steren Epstein Becker Law Firm Health Care Litigation

E. John Steren

Member

Epstein Becker & Green, P.C.

Website

www.ebglaw.com

Organization Profile

Full Profile

Connect

Email

202-861-1825

Professional Biography

E. John Steren is a Member of the Firm in the Health Care & Life Sciences and Litigation & Business Disputes practices, in the Washington, DC, office of Epstein Becker Green. Mr. Steren devotes a significant portion of his practice to helping health care organizations manage the antitrust risks of joint ventures and other business arrangements. He also focuses his practice on other complex commercial and civil litigation matters.

More Legal and Business Bylines From E. John Steren

Diagnosing Health Care Podcast – Episode 75: Key Changes in Finalized Antitrust Merger Guidelines [Podcast] - (Posted On Thursday, April 11, 2024)
FTC Continues Investigation into PBM Practices - (Posted On Thursday, March 21, 2024)
Agencies Focus on Private Equity in Health Care - (Posted On Thursday, March 07, 2024)
FTC Calls on Congress to “Modernize” HSR Act and Extend Waiting Periods - (Posted On Thursday, February 15, 2024)
Revised HSR Thresholds Announced - (Posted On Thursday, February 01, 2024)
Updated Merger Guidelines Finalized - (Posted On Thursday, January 18, 2024)
President Seeks More Antitrust Scrutiny of Health Care Transactions - (Posted On Thursday, December 14, 2023)
Latest Status of Proposed Merger Guidelines - (Posted On Thursday, November 30, 2023)
FTC Chairwoman Defends Agency’s Enforcement Record - (Posted On Thursday, November 16, 2023)
Major Changes in Antitrust Premerger Notification Filing [Podcast] - (Posted On Friday, November 10, 2023)

FTC Regulation

FTC Coverage and Updates

The National Law Review awards Epstein Becker & Green attorneys E. John Steren and Patricia M. Wagner with a Go-To Thought Leadership award for their coverage of a range of competition law topics including personnel changes at the FTC and the large uptick in Hart-Scott-Rodino (“HSR”) filings the FTC received in 2021. Exceptionally helpful to the NLR's readers in 2021 were Mr. Steren's & Ms. Wagner's actionable insights on how the new direction at the FTC impacts the pharmaceutical and healthcare industries.